Data / Drug companies / CMP Pharma, Inc.
CMP Pharma, Inc.: 11 products in the FDA NDC directory, labeler code 46287
CMP Pharma, Inc. (labeler code 46287) lists 11 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 11 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on August 28, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 46287
- Products in commercial distribution
- 11
- Packages
- 17
- Finished drugs by generic name
- 9
- Prescription products
- 11
- Over the counter products
- 0
- Flagged as original packager
- 11 of 11 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- December 8, 1982
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 6 | 54.5% |
| Generic drugs (ANDA) | 4 | 36.4% |
| Other unapproved drugs | 1 | 9.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 11 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Amlodipine | 2 | 3 |
| Sodium polystyrene sulfonate | 2 | 13 |
| Citric acid and sodium citrate | 1 | 1 |
| Triamcinolone acetonide | 1 | 77 |
| Tadalafil | 1 | 54 |
| Clonidine hydrochloride | 1 | 45 |
| Carospir | 1 | 1 |
| Atorvaliq | 1 | 1 |
| Isoniazid | 1 | 15 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 5 | 45.5% |
| Suspension | 4 | 36.4% |
| Ointment | 1 | 9.1% |
| Powder, for suspension | 1 | 9.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Qlonilik | 46287-085 | Solution | New drug applications (NDA) | August 28, 2026 |
| Norliqva | 46287-037 | Solution | New drug applications (NDA) | March 2, 2026 |
| Atorvaliq | 46287-030 | Suspension | New drug applications (NDA) | March 1, 2023 |
| Tadliq | 46287-045 | Suspension | New drug applications (NDA) | August 30, 2022 |
| Norliqva | 46287-035 | Solution | New drug applications (NDA) | April 15, 2022 |
| Triamcinolone Acetonide | 46287-010 | Ointment | Generic drugs (ANDA) | August 23, 2021 |
| CaroSpir | 46287-020 | Suspension | New drug applications (NDA) | August 4, 2017 |
| Sodium Polystyrene Sulfonate | 46287-012 | Powder, for suspension | Generic drugs (ANDA) | January 19, 1989 |
| Oracit | 46287-014 | Solution | Other unapproved drugs | May 15, 1984 |
| Isoniazid | 46287-009 | Solution | Generic drugs (ANDA) | November 11, 1983 |
| Sodium Polystyrene Sulfonate | 46287-006 | Suspension | Generic drugs (ANDA) | December 8, 1982 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.